China REgistry of WATCHMAN (CREW)

  • End date
    Dec 21, 2023
  • participants needed
  • sponsor
    Fu Wai Hospital, Beijing, China
Updated on 27 January 2022
vascular disease
left atrial appendage closure


This registry is designed to observe the safety and effectiveness of WATCHMAN left atrial appendage closure technology in a Chinese population.


In this prospective, multi-center, single arm observational study, 413 patients with non-valvular atrial fibrillation intended to be implanted with a WATCHMAN device based on real clinical practice will be enrolled. Enrolled subjects will be followed up for 5 years.Primary endpoints include stroke, systematic embolism, cardiovascular death, and procedure or device related complications, etc.

Condition Atrial Fibrillation, Left Atrial Appendage Closure
Treatment left atrial appendage closure device implantation
Clinical Study IdentifierNCT03014557
SponsorFu Wai Hospital, Beijing, China
Last Modified on27 January 2022


Yes No Not Sure

Inclusion Criteria

Non-valvular atrial fibrillation patient with CHA2DS2-VASC2, and with any one
of the following items
not suitable for long-term anti-coagulation therapy
stroke or embolism events in spite of warfarin treatment with intended INR

Exclusion Criteria

Patient with any one of the following items will be excluded from the study
clinical exclusion criteria (any of the items) a congestive heart failure NYHA IV, b atrial septum defect, ASD surgery or closure c cardioversion or catheter ablation is planned within 30 days d with mechanic valve e left atrial appendage resection f heart transplantation g symptomatic jugular artery disease h previous stroke or TIA within 30 days i long term warfarin therapy is needed or contraindicated to warfarin j contraindicated to aspirin or clopidogrel k enrolled in other cardiac device or medicine trials l pregnant women or plan to pregnant during the study period m estimated life < 5 years
Echocardiography exclusion criteria (any of the items) a LVEF<30% b thrombus
or spontaneous echo imaging detected within two days prior to procedure c
patent foramen ovale d cardiac tumor e left atrial appendage orifice diameter
>32mm or < 17mm f the depth of left atrial appendage is less than the width g
prominent mitral stenosis (area <1.5cm2)
subject is not able to or will not complete the follow ups as planned
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note